Amylin Pharmaceuticals to Present at BIOCOM Investor Conference

SAN DIEGO, Oct. 23 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(Nasdaq: AMLN) will be presenting at the BIOCOM Investor Conference in San
Diego on Tuesday, October 28, 2008 at 10:30 a.m. PT. Mark G. Foletta, Amylin's
Senior Vice President of Finance and Chief Financial Officer, will be
providing a corporate overview.
The live presentation will be Web cast, and a recording will be made
available following the event. The Web cast and recording will be accessible
through Amylin's corporate Web site, located at http://www.amylin.com. To
access the live Web cast, please log on to Amylin's site approximately fifteen
minutes prior to the presentation to register and download any necessary audio
software.
About Amylin Pharmaceuticals
Amylin Pharmaceuticals is a biopharmaceutical company committed to
improving lives through the discovery, development and commercialization of
innovative medicines. Amylin has developed and gained approval for two
first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate)
injection and BYETTA(R) (exenatide) injection. Amylin's research and
development activities leverage the company's expertise in metabolism to
develop potential therapies to treat diabetes and obesity. Amylin is
headquartered in San Diego, California with over 2,000 employees nationwide.
Further information on Amylin Pharmaceuticals is available at
http://www.amylin.com.
SOURCE Amylin Pharmaceuticals, Inc.

Michael York, Senior Director, Investor Relations of Amylin Pharmaceuticals,
Inc., +1-858-552-2200, ext. 8602